DAYBUE STIX (Trofinetide) Patent Expiration, LOE Window & CMS Spending

DAYBUE STIX (Trofinetide) by Acadia Pharmaceuticals: FDA Orange Book core substance LOE 2043-01-12, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $58,779 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAcadia Pharmaceuticals
FDA Application & PathwayN219884 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2043-01-12
Last Listed Patent or Exclusivity Date2043-01-12
Orange Book Patents (*PED Extensions)24 patents (12 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($58,779 intro WAC)